For EGFR wild-type adenocarcinoma patients, CEA (HR = 2.150, P < 0.001 for DFS; HR = 1.711, P = 0.002 for OS) and clinical stage (HR = 1.527, P = 0.020 for DFS; HR = 1.593, P = 0.026 for OS) were independently predictive and prognostic. Here, CEACAM5 is linked to adenocarcinoma.